East Asia Pharmaceutical: Net loss of 82.392 million yuan in 2025.

East Asia Pharmaceutical announced that its operating income in 2025 was 940 million yuan, a year-on-year decrease of 21.54%. The net loss attributable to shareholders of the listed company was 82.392 million yuan, compared to a net loss of 101 million yuan in the same period last year. The company does not plan to distribute profits for the year 2025, nor will it increase capital reserves or make any other form of distribution.